Effects of Morphine

Morphine is a commonly used analgesic belonging to the opioid class of alkaloids and acts as an opioid receptor agonist. Its potent analgesic effect is primarily achieved by stimulating opioid receptors in the central nervous system. Morphine is effective against all types of pain, but it demonstrates superior efficacy for persistent (chronic) pain compared with intermittent pain relief medications. It is particularly effective for severe pain and visceral pain.

Pharmacological Effects of Morphine

Morphine is an opioid analgesic primarily indicated for moderate-to-severe pain management. It is widely used for cancer-related pain and postoperative pain relief. However, due to its respiratory depressant effect and ability to induce spasm of the sphincter of Oddi, morphine is contraindicated in patients with respiratory failure or biliary tract disease.

Morphine exerts pronounced effects on the central nervous system and smooth muscle—particularly gastrointestinal smooth muscle. Clinically, it provides significant analgesia and sedation for cancer pain patients, effectively alleviating anxiety, tension, and other emotional responses associated with pain. Its respiratory depressant effect necessitates careful dose titration during administration. Additionally, its antitussive action results from suppression of the respiratory center.

In the gastrointestinal tract, morphine produces effective antidiarrheal effects, primarily by stimulating gastrointestinal smooth muscle and increasing its tone. Morphine also exerts notable effects on the cardiovascular system. Therefore, clinical use must be strictly guided by physicians to maximize therapeutic benefit. However, because morphine is an opioid with high addiction potential, its use is subject to stringent regulatory control.

Precautions for Morphine Use

1. Children and elderly patients exhibit slower drug clearance and prolonged half-life, rendering them more susceptible to respiratory depression.

2. Morphine readily crosses the placental barrier, potentially affecting the fetus and inducing fetal drug dependence; newborns may display immediate withdrawal symptoms after birth.

3. When used for visceral colic (e.g., biliary or renal colic), morphine should be co-administered with antispasmodic agents such as atropine, and treatment duration should be kept brief.

4. Morphine should not be administered until at least 2–3 weeks after discontinuation of monoamine oxidase inhibitors (MAOIs).

5. Extended-release and controlled-release tablets must be swallowed whole; they must not be cut, crushed, or chewed.

6. Morphine injection must not be mixed for co-administration with chlorpromazine, promethazine, aminophylline, barbiturates, phenytoin sodium, sodium bicarbonate, heparin sodium, pethidine, sulfadiazine, or other listed agents.

7. Close monitoring of respiratory and circulatory function is mandatory during epidural or intrathecal administration of morphine.

8. Concomitant use of morphine with phenothiazines, sedative-hypnotics, tricyclic antidepressants, antihistamines, barbiturate anesthetics, pethidine, codeine, methadone, or fentanyl requires dosage reduction.

9. Acute morphine toxicity manifests as coma, respiratory depression, extreme miosis (pinpoint pupils), hypotension, cyanosis, oliguria, hypothermia, clammy skin, and muscle weakness. Ultimately, shock, circulatory collapse, mydriasis (pupil dilation), and death may occur. Individual sensitivity to morphine’s toxic effects varies considerably.

The above outlines the pharmacological effects and key considerations for morphine use. We hope this information proves helpful.